Logo image of 56S1.DE

SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis

Europe - FRA:56S1 - FR0013154002 - Common Stock

195.2 EUR
+5 (+2.63%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 56S1. 56S1 was compared to 20 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 shows excellent growth, but is valued quite expensive already. These ratings could make 56S1 a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year 56S1 was profitable.
56S1 had a positive operating cash flow in the past year.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

The Return On Assets of 56S1 (2.71%) is worse than 61.11% of its industry peers.
56S1 has a Return On Equity (5.63%) which is in line with its industry peers.
56S1 has a Return On Invested Capital of 4.60%. This is comparable to the rest of the industry: 56S1 outperforms 44.44% of its industry peers.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 7.27%.
The last Return On Invested Capital (4.60%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
Industry RankSector Rank
ROA 2.71%
ROE 5.63%
ROIC 4.6%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

56S1 has a better Profit Margin (7.78%) than 61.11% of its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1 has a Operating Margin of 14.71%. This is comparable to the rest of the industry: 56S1 outperforms 55.56% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
56S1 has a better Gross Margin (44.63%) than 72.22% of its industry peers.
56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.71%
PM (TTM) 7.78%
GM 44.63%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
56S1 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 3.96 indicates that 56S1 is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.96, 56S1 is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 5.98, which is a neutral value as it means it would take 56S1, 5.98 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 56S1 (5.98) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.71 indicates that 56S1 is somewhat dependend on debt financing.
56S1 has a Debt to Equity ratio (0.71) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 5.98
Altman-Z 3.96
ROIC/WACC0.53
WACC8.68%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.91 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1 has a better Current ratio (1.91) than 88.89% of its industry peers.
56S1 has a Quick Ratio of 1.18. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, 56S1 is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.18
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

7

3. Growth

3.1 Past

56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.91%, which is quite impressive.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 5.44%.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)25.91%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%38.82%
Revenue 1Y (TTM)5.44%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%5.46%

3.2 Future

Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.23% on average per year.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.45% yearly.
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 47.26, the valuation of 56S1 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 72.22% of the companies listed in the same industry.
56S1 is valuated expensively when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 36.37, the valuation of 56S1 can be described as expensive.
56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 72.22% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, 56S1 is valued quite expensively.
Industry RankSector Rank
PE 47.26
Fwd PE 36.37
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 61.11% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 38.27
EV/EBITDA 28.69
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.71
PEG (5Y)11.27
EPS Next 2Y23.83%
EPS Next 3Y23.3%

3

5. Dividend

5.1 Amount

With a yearly dividend of 0.36%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is slightly below the industry average, which is at 0.71.
Compared to an average S&P500 Dividend Yield of 2.44, 56S1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.36%

5.2 History

The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.5 1

5.3 Sustainability

29.77% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP29.77%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

SARTORIUS STEDIM BIOTECH

FRA:56S1 (10/3/2025, 7:00:00 PM)

195.2

+5 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-22 2025-07-22/bmo
Earnings (Next)10-16 2025-10-16
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.00B
Analysts81.11
Price Target239.46 (22.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.36%
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP29.77%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.2%
Min EPS beat(2)10.22%
Max EPS beat(2)22.18%
EPS beat(4)3
Avg EPS beat(4)8.6%
Min EPS beat(4)-5.62%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-10.02%
EPS beat(12)3
Avg EPS beat(12)-13.27%
EPS beat(16)5
Avg EPS beat(16)-12.35%
Revenue beat(2)2
Avg Revenue beat(2)1.91%
Min Revenue beat(2)0.3%
Max Revenue beat(2)3.52%
Revenue beat(4)3
Avg Revenue beat(4)0.4%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.47%
Revenue beat(16)8
Avg Revenue beat(16)12%
PT rev (1m)0.2%
PT rev (3m)1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.15%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)4.65%
Revenue NQ rev (3m)2.36%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE 47.26
Fwd PE 36.37
P/S 6.56
P/FCF 38.27
P/OCF 24.11
P/B 4.75
P/tB N/A
EV/EBITDA 28.69
EPS(TTM)4.13
EY2.12%
EPS(NY)5.37
Fwd EY2.75%
FCF(TTM)5.1
FCFY2.61%
OCF(TTM)8.1
OCFY4.15%
SpS29.76
BVpS41.13
TBVpS-4.66
PEG (NY)1.71
PEG (5Y)11.27
Profitability
Industry RankSector Rank
ROA 2.71%
ROE 5.63%
ROCE 5.78%
ROIC 4.6%
ROICexc 5.12%
ROICexgc 15.67%
OM 14.71%
PM (TTM) 7.78%
GM 44.63%
FCFM 17.14%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score7
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 5.98
Debt/EBITDA 3.84
Cap/Depr 93.43%
Cap/Sales 10.07%
Interest Coverage 2.82
Cash Conversion 106.77%
Profit Quality 220.28%
Current Ratio 1.91
Quick Ratio 1.18
Altman-Z 3.96
F-Score7
WACC8.68%
ROIC/WACC0.53
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)25.91%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%38.82%
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue 1Y (TTM)5.44%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%5.46%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
EBIT growth 1Y7.47%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.7%
FCF growth 1Y202.01%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y16.41%
OCF growth 3Y5.11%
OCF growth 5Y21.32%